MA51413A - Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique - Google Patents

Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique

Info

Publication number
MA51413A
MA51413A MA051413A MA51413A MA51413A MA 51413 A MA51413 A MA 51413A MA 051413 A MA051413 A MA 051413A MA 51413 A MA51413 A MA 51413A MA 51413 A MA51413 A MA 51413A
Authority
MA
Morocco
Prior art keywords
phenyl
treatment
cystic fibrosis
alkyl alcohol
alcohol derivatives
Prior art date
Application number
MA051413A
Other languages
English (en)
Inventor
Serena Bertolini
Claudio Sorio
Gino Villetti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA51413A publication Critical patent/MA51413A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051413A 2017-12-28 2018-12-19 Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique MA51413A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17210827 2017-12-28

Publications (1)

Publication Number Publication Date
MA51413A true MA51413A (fr) 2021-04-28

Family

ID=60813721

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051413A MA51413A (fr) 2017-12-28 2018-12-19 Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique

Country Status (5)

Country Link
US (2) US20210038575A1 (fr)
EP (1) EP3732164A1 (fr)
BR (1) BR112020012972A2 (fr)
MA (1) MA51413A (fr)
WO (1) WO2019129586A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61558B1 (sr) * 2013-10-22 2021-04-29 Chiesi Farm Spa Kristalni oblik pde4 inhibitora
CN115466169B (zh) * 2021-06-10 2024-03-26 中国医学科学院药物研究所 取代邻苯二酚醚类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044023B1 (fr) 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivés d'alcools de 1-phényl-2-pyridynyl alkylène en tant qu'inhibiteurs de phosphodiestérase
EP2022783A1 (fr) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase
EP2216327A1 (fr) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase
EP2928869B1 (fr) * 2012-12-05 2019-02-20 Chiesi Farmaceutici S.p.A. Dérivés d'alcool 1-phényl-2-pyridinyl alkylique en tant qu'inhibiteurs de phosphodiestérase
EP3142748B1 (fr) 2014-05-15 2019-09-11 Celgene Corporation Utilisation d'inhibiteurs de pde4 et de leurs combinaisons pour le traitement de la fibrose kystique

Also Published As

Publication number Publication date
RU2020123677A3 (fr) 2022-01-28
RU2020123677A (ru) 2022-01-28
EP3732164A1 (fr) 2020-11-04
WO2019129586A1 (fr) 2019-07-04
US20220218678A1 (en) 2022-07-14
BR112020012972A2 (pt) 2020-11-24
US20210038575A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3558313A4 (fr) Substances pour le traitement d'affections liées à la stéatose hépatique
EP3442488A4 (fr) Compositions pour l'application topique de composés
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3013345A4 (fr) Composés pour le traitement d'une amyotrophie spinale
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3634426A4 (fr) Compositions pour le traitement d'une fibrose
EP3454896A4 (fr) Dérivés hétérocycliques pour le traitement de rsv
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP2968321A4 (fr) Composés pour le traitement de maladies de fibrose
EP3378484A4 (fr) Composition pharmaceutique pour le traitement de la fibrose cardiaque
EP3898991A4 (fr) Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3805216A4 (fr) Composés pour le traitement ou la prévention de maladies hépatiques
MA51738A (fr) Composés pour le traitement de la douleur
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3302488A4 (fr) Nouvelle utilisation de dérivés aryl-quinoléine comme inhibiteurs de l'imitation de facteurs vasculogènes
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques